Medicine and Dentistry
Non Muscle Invasive Bladder Cancer
90%
Bladder Cancer
72%
Transurethral Resection
72%
Recurrent Disease
68%
Transitional Cell Carcinoma
68%
Neoplasm
66%
Cystectomy
60%
Diseases
55%
Carcinoma in Situ
49%
Bladder
49%
Bladder Tumor
48%
Urology
45%
Chemotherapy
32%
Upper Urinary Tract
26%
Mycobacterium Bovis BCG
25%
Cystoscopy
24%
Predictive Factor
23%
Prognostic Factor
21%
Intravesical Drug Administration
17%
Prostate Cancer
17%
Muscle Invasive Bladder Cancer
16%
Consultation
16%
Bladder Carcinoma
16%
Nephroureterectomy
15%
Superficial Bladder Cancer
15%
Conservative Treatment
14%
Prostatectomy
14%
Pelvis
13%
Ureter
13%
Multivariate Analysis
12%
Malignant Neoplasm
12%
Incision
12%
Retrospective Study
11%
Cancer Specific Survival
11%
Operation Duration
11%
Ileal Conduit
11%
Surgical Anastomosis
10%
Retroperitoneal Lymph Node Dissection
10%
Kidney Tumour
10%
Maintenance Therapy
10%
Neobladder
9%
End Stage Renal Disease
9%
Surgery
9%
Radiation Therapy
9%
Urinary System
9%
Observational Study
8%
Clear Cell Renal Cell Carcinoma
8%
Aminolevulinic Acid Hexyl Ester
8%
Partial Nephrectomy
8%
Urologist
8%
Keyphrases
Non-muscle Invasive Bladder Cancer (NMIBC)
100%
Transurethral Resection
61%
Upper Tract Urothelial Carcinoma
56%
Bacillus Calmette
55%
Bladder Cancer
53%
Carcinoma in Situ
42%
Tumor
32%
Radical Cystectomy
32%
Bladder Tumor
32%
European Association of Urology
30%
Cystectomy
23%
Predictive Factors
22%
Bladder
22%
European Association of Urology Guidelines
19%
Intermediate Risk
19%
Transurethral Resection of Bladder Tumor (TURBT)
18%
Prognostic Factors
17%
Muscle-invasive Bladder Cancer
17%
Intravesical
17%
Chemotherapy
16%
Superficial Bladder Cancer
16%
Robot-assisted Radical Cystectomy
16%
American Urological Association
15%
Bacillus Calmette-Guérin
15%
Multivariate Analysis
14%
Cystoscopy
14%
Radical Prostatectomy
14%
Oncologic
14%
Nephroureterectomy
14%
Invasive Urothelial Carcinoma
14%
International Consultation
13%
Cancer-specific Survival
13%
Cystitis
13%
High-risk Non-muscle-invasive Bladder Cancer
13%
Prostatic Urethra
12%
Current Guidelines
11%
Neobladder
11%
Ileal Conduit
11%
Functional Outcome
11%
Escherichia Coli
11%
Evidence Acquisition
10%
Urothelial Carcinoma
10%
Hospital Stay
10%
Mecillinam
10%
Fosfomycin
10%
High-risk Bladder Cancer
10%
T1G3
10%
Maintenance Therapy
9%
Intravesical Instillation
9%
Cystoprostatectomy
9%
